Statements (23)
Predicate | Object |
---|---|
gptkbp:instanceOf |
gptkb:chemical_compound
|
gptkbp:approvalYear |
2018
|
gptkbp:approvedBy |
gptkb:FDA
|
gptkbp:ATCCode |
L01ED10
|
gptkbp:CASNumber |
gptkb:936091-26-8
|
gptkbp:developedBy |
gptkb:Pfizer
|
gptkbp:hasInChIKey |
QXJYYZQYKJYFMA-UHFFFAOYSA-N
|
gptkbp:hasMolecularFormula |
C21H19FN6O2
|
gptkbp:hasSMILES |
CC1=NN2C(=N1)C3=C(C(=NC(=C3)N)N2C)C4=CC(=C(C=C4)F)C(=O)N
|
gptkbp:hasUNII |
6Z5B6HVF6O
|
https://www.w3.org/2000/01/rdf-schema#label |
936091-26-8
|
gptkbp:isALKInhibitor |
true
|
gptkbp:isROS1Inhibitor |
true
|
gptkbp:IUPACName |
(10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4',3':4,5]pyrrolo[2,1-f][1,2,4]triazolo[1,5-c][1,3]benzoxazin-4(3H)-one
|
gptkbp:molecularWeight |
406.42 g/mol
|
gptkbp:PubChem_CID |
gptkb:CHEMBL3544943
gptkb:DB12173 71587765 |
gptkbp:synonym |
gptkb:Lorlatinib
PF-06463922 |
gptkbp:usedFor |
treatment of non-small cell lung cancer
|
gptkbp:bfsParent |
gptkb:fedratinib
|
gptkbp:bfsLayer |
7
|